Business Wire

MUNDIPHARMA

24.4.2024 22:02:28 CEST | Business Wire | Press release

Share
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics.

This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafungin is a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1

Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune system and the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8

“This acquisition places Mundipharma in the best position to realise the full potential of rezafungin including its availability and ongoing development. We are committed to ensuring patients affected with invasive candidiasis have access to an additional treatment option to manage this potentially life-threatening condition,” said Marc Princen, Chief Executive Officer at Mundipharma.

Rezafungin received approval by the U.S. Food and Drug Administration (FDA) in March 20239 and the European Commission (EC) in December 202310. It has also been authorised for use by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in January 202411 and the UAE Ministry of Health and Prevention (MOHAP) in March 2024. Rezafungin has been granted Orphan Drug Designation for the treatment of invasive candidiasis in the US12, EU13 and UK.14 It is currently available to patients in the UK and Germany, and further marketing authorisation applications are subject to accelerated review procedures to support getting this important medicine to patients.

Commercialisation rights to rezafungin in the United States will remain licensed to Melinta Therapeutics.

*Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.

*ENDS*

About invasive candidiasis

Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is 40%4 or more.5,6 IC is characterised as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues, known as candidemia and deep-seated tissue candidiasis.15

About Mundipharma

Mundipharma is a global healthcare company focussing on customers across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East.

Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease as well as other severe and debilitating disease areas. Their guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything they do. For more information visit www.mundipharma.com.

References:

  1. REZZAYO® Product Information. EPAR Medicine Overview available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo (last accessed April 2024).
  2. Pappas PG, et al. Nat Rev Dis Primers 2018 ;4 :18026.
  3. CDC. Invasive candidiasis. Available at: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/definition.html (last accessed April 2024).
  4. Kullberg BJ, Arendrup MC. N Engl J Med 2015;373:1445–56.
  5. Bassetti M, et al. Crit Care 2019;23(1):219.
  6. Cortegiani A, et al. Cochrane Database Syst Rev 2016;2016:Cd004920.
  7. Bassetti M, et al. J Antimicrob Chemother 2018; 73 Suppl 1: i14–i25 doi:10.1093/jac/dkx445.
  8. Ham YY, et al. Future Microbiology 2021;16(1):27–36.
  9. US Food and Drug Administration approval. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217417Orig1s000Approv.pdf (last accessed April 2024)
  10. European Medicines Agency approval. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo#ema-inpage-item-assessment-history (last accessed April 2024).
  11. UK Medicines and Healthcare Products Regulatory Agency authorisation. Available at: https://www.gov.uk/government/news/rezzayo-approved-to-treat-adult-patients-with-invasive-candidiasis (last accessed April 2024).
  12. US Food and Drug Administration. Orphan drug designation notice. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=507215 (last accessed April 2024)
  13. European Commission. Orphan maintenance assesment report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rezzayo (last accessed April 2024).
  14. UK MHRA. Register of orphan medicinal products. Available at: https://www.gov.uk/government/publications/orphan-registered-medicinal-products/orphan-register#rezzayo (last accessed April 2024).
  15. Cortes JA, Corrales IF. Invasive candidiasis: Epidemiology and Risk Factors. November 2018. Available at https://www.intechopen.com/chapters/64365 (last accessed April 2024).

Job reference: SciA-RZF-2400003
Date of preparation: April 2024

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424542362/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Healthcare Accelerates AI Investment as Governance and Risk Shape the Path to Value19.11.2026 10:26:00 CET | Press release

HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory complexity, validation requirements, and organizational readiness HTEC, the global AI technology and engineering leader, today released new research examining how healthcare and life sciences organizations measure, track, and realize value from AI investments, as well as the risks and barriers preventing them from doing so at scale. The findings reveal that while investment continues to rise, organizations that successfully scale AI focus not only on technology, but also on the governance, workforce adoption, and operational foundations needed to track, prove, and realize impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119322683/en/ HTEC research finds 83% of healthcare and life sciences organizations have increased AI investment, yet adoption is still shaped by regulatory c

Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release

Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit

Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 10:00:00 CET | Press release

Twilio Segment gives Chelsea a more connected view of its global fanbase for real-time responses to personal interests and match moments on the pitch Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to t

EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 09:49:00 CET | Press release

Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI

Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 09:43:00 CET | Press release

Expanding Alipay+'s national QR scheme connections to 16, spanning Asia, the Middle East and Latin AmericaEnabling international travellers to pay with home wallets at Pix merchants across Brazil, supporting local businesses and inbound tourism Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloadi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye